Potential role of immunotherapy in advanced non-small-cell lung cancer
| Autor: | Ana Flávia de Holanda Veloso, Paulo Esrom Catarina, Ramon Andrade de Mello, Georgios Antoniou, Sara Nadine |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Nsclc Afatinib Tumor escape Review Pembrolizumab Anti-Pd-1 Immune checkpoint inhibitors 03 medical and health sciences 0302 clinical medicine Gefitinib PDL1 medicine Anaplastic lymphoma kinase Pharmacology (medical) ipilimumab Lung cancer nivolumab CTLA4 clinical trials Suppression Crizotinib Ceritinib business.industry Immunosurveillance medicine.disease Management PD1 Predictive biomarker Nivolumab 030104 developmental biology non-small-cell lung cancer Oncology 030220 oncology & carcinogenesis Immunology Cancer research immunotherapy pembrolizumab Erlotinib business Ifn-gamma medicine.drug |
| Zdroj: | Repositório Científico de Acesso Aberto de Portugal Repositório Científico de Acesso Aberto de Portugal (RCAAP) instacron:RCAAP OncoTargets and therapy |
| ISSN: | 1178-6930 |
| DOI: | 10.2147/ott.s90459 |
| Popis: | Immuno checkpoint inhibitors have ushered in a new era with respect to the treatment of advanced non-small-cell lung cancer. Many patients are not suitable for treatment with epidermal growth factor receptor tyrosine kinase inhibitors (eg, gefitinib, erlotinib, and afatinib) or with anaplastic lymphoma kinase inhibitors (eg, crizotinib and ceritinib). As a result, anti-PD-1/PD-L1 and CTLA-4 inhibitors may play a novel role in the improvement of outcomes in a metastatic setting. The regulation of immune surveillance, immunoediting, and immunoescape mechanisms may play an interesting role in this regard either alone or in combination with current drugs. Here, we discuss advances in immunotherapy for the treatment of metastatic non-small-cell lung cancer as well as future perspectives within this framework. Video abstract |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|